A miss for Roche’s Akt inhibitor in advanced breast cancer leaves questions over population and combination.
Licensing deal could enable bundling of antipsychotics with management technology.
Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's…
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.